Drugs / Tianenfu
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT05433597 Comparator | Jul 2022 → Jul 2024 overdue | nasopharyngeal carcinoma | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tianenfu | “Tianenfu is a novel recombinant modified human tumor necrosis with high activity and low toxicity.” NCT05433597 ↗ |
| Route | Intramuscular | “intramuscular” NCT05433597 ↗ |